1. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. Issue 11 (9th September 2018) Authors: Cortes, Jorge E.; Douglas Smith, B.; Wang, Eunice S.; Merchant, Akil; Oehler, Vivian G.; Arellano, Martha; DeAngelo, Daniel J.; Pollyea, Daniel A.; Sekeres, Mikkael A.; Robak, Tadeusz; Ma, Weidong Wendy; Zeremski, Mirjana; Naveed Shaik, M.; Douglas Laird, A.; O'Connell, Ashleigh; Chan, Geoffrey; ... Journal: American journal of hematology Issue: Volume 93:Issue 11(2018:Nov.) Page Start: 1301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. (2nd September 2019) Authors: Cortes, Jorge E.; Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Crescenzo, Rocco J.; Su, Yun; Gambacorti-Passerini, Carlo; Heeg, Bart; Douglas Smith, B. Journal: Current medical research and opinion Issue: Volume 35:Number 9(2019) Page Start: 1615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Myelodysplastic syndromes: What do hospitalists need to know?. Issue 6 (11th May 2013) Authors: Zeidan, Amer M.; Faltas, Bishoy; Douglas Smith, B.; Gore, Steven Journal: Journal of hospital medicine Issue: Volume 8:Issue 6(2013) Page Start: 351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗